Helex is extending the frontier of breakthrough genetic medicines to meet the significant underserved medical needs of patients with chronic kidney diseases, which affect 1 in 7 individuals globally. Helex leverages its proprietary lipid nanoparticles (LNP) delivery technology, tunable to various kidney cell types, and the Epic-Cure™ gene editing drug design platform to develop in vivo gene editing-based therapeutics for renal indications. Lead asset is a pioneering first-in-class, potential single-dose therapeutic for Autosomal Dominant Polycystic Kidney Disease (ADPKD). Helex's founders hail from King’s College London and have known each other for over a decade. The management and advisors have over 50 years of combined experience in gene therapy, nonviral delivery, and strategy. Helex has raised $3 million in pre-seed led by SOSV, won the XSeed award by Deerfield Management, and the Targeted Genome Editor Delivery Challenge by NIH.